Stockholm3 blood test detected 90% of aggressive prostate cancer cases compared to 74% for PSA tests in a study of over ...

NeoGenomics, Inc.(NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the launch of PTEN IHC CDx, the first immunohistochemistry (IHC) ...

Researchers at the University of British Columbia have identified a new form of hereditary prostate cancer that, while rare, ...

The Stockholm3 model combines PSA, plasma protein biomarkers, polygenic risk, and clinical factors for prostate cancer screening.

PSA levels can be elevated for reasons other than cancer, such as an enlarged or inflamed prostate. False positive and false negative PSA test results are possible. The American Cancer Society does ...

CorePlus, Puerto Rico’s fully digital precision pathology and clinical laboratory, announced today the integration of the ...

According to the institute, a single, reliable test to differentiate aggressive, life-threatening cancers from slower-growing ...

A large analysis suggests that a multivariable risk assessment tool, called Stockholm3, can detect substantially more ...

Only about 6% of men have had a documented discussion with their primary care doctor about prostate cancer screening, even though guidelines recommend this talk for all men between 55 and 69 years of ...

Black men are much more likely to die from prostate cancer than the general population. A group of Chicago-area researchers ...

Prostate cancer is often called a “silent killer,” and for good reason. You don’t get a big set of warnings, and for a lot of ...